Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer

European Journal of Cancer

Volumn 43, Issue 1, 2007, Pages 64-70

  Robertson, J F R ^a   Semiglazov, V ^b   Nemsadze, G ^c   Dzagnidze, G ^c   Janjalia, M ^c   Nicholson, R I ^d   Gee, J M W ^d   Armstrong, J ^e  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c Department of Urology   (Georgia)

^d Tenovus Cancer Research Centre   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Breast cancer; Fulvestrant; Ki67; Oestrogen receptor; Premenopausal; Progesterone receptor

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; FULVESTRANT; KI 67 ANTIGEN; LUTEINIZING HORMONE; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; BACKACHE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CHOLECYSTITIS; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HORMONE SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; BLOOD; BREAST TUMOR; FOLLICULAR PHASE; LUTEAL PHASE; METABOLISM; MIDDLE AGED;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FOLLICULAR PHASE; HUMANS; KI-67 ANTIGEN; LUTEAL PHASE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 33846023025     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.08.019     Document Type: Article

References (26)

1. Fuqua S.A., Fitzgerald S.D., Allred D.C., et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52 (1992) 483-486
2. Wakeling A.E., Dukes M., and Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 51 (1991) 3867-3873
3. Fisher B., Jeong J.H., Dignam J., et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 30 (2001) 62-66
4. Howell A., Osborne C.K., Morris C., and Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 89 (2000) 817-825
5. Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61 (2001) 6739-6746
6. DeFriend D.J., Howell A., Nicholson R.I., et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54 (1994) 408-414
7. Gutteridge E., Robertson J.F.R., Cheung K.L., Pinder S., Ellis I.O., and Wakeling A.E. Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer - final results. Breast Cancer Res Treat 88 Suppl. 1 (2004) [abstract 4086]
8. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
9. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
10. Perey L., Paridaens R., Nolé F., et al. Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 88 Suppl 1 (2004) [abstract 6048]
11. Steger G.G., Bartsch R., Wenzel C., et al. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 41 (2005) 2655-2661
12. Steger G.G., Gips M., Simon S.D., et al. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 31 Suppl. 2 (2005) S10-S16
13. Ingle J.N., Suman V.J., Rowland K.M., et al. North Central Cancer Treatment Group Trial N0032. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24 (2006) 1052-1056
14. DeRosa C.M., Ozzello L., Habif D.V., Konrath J.G., and Greene G.L. Immunohistochemical assessment of estrogen and progesterone receptors in stored imprints and cryostat sections of breast carcinomas. Ann Surg 210 (1989) 224-228
15. al Saati T., Clamens S., Cohen-Knafo E., et al. Production of monoclonal antibodies to human estrogen-receptor (ER) using recombinant ER. Int J Cancer 55 (1993) 651-654
16. Goulding H., Pinder S., Cannon P., et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26 (1995) 291-294
17. Press M., Spaulding B., Groshen S., et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 67 (2002) 799-813
18. Cattoretti G., Becker M.H., Key G., et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168 (1992) 357-363
19. Pinder S.E., Wencyk P., Sibbering A., et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71 (1995) 146-149
20. Renshaw L., Young O.E., Macaskill J., and Dixon J.M. Pre-operative study of the tolerability of Faslodex and tamoxifen in a group of pre-menopausal women. Eur J Cancer 3 (2005) 22 [abstract O-70]
21. Donnez J., Hervais Vivancos B., Kudela M., et al. A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with fibroids awaiting hysterectomy. Fertil Steril 79 (2003) 1380-1389
22. Mandlekar S., and Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 (2001) 469-477
23. Dowsett M., Howell R., Salter J., Thomas N.M., and Thomas E.J. Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo. Hum Reprod 10 (1995) 262-267
24. Thomas E.J., Walton P.L., Thomas N.M., and Dowsett M. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod 9 (1994) 1991-1996
25. Addo S., Yates R.A., and Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87 (2002) 1354-1359
26. de Lima G.R., Facina G., Shida J.Y., et al. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 39 (2003) 891-898